UCSD Eye Doctor Resigns After Investigation into Ties with China

The FDA and the university have audited Kang Zhang for breaches in bioethics and a failure to follow research protocols.

Written byNicoletta Lanese
| 4 min read
zhang

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Prominent University of California, San Diego, eye doctor Kang Zhang resigned on July 4 after inewsource raised questions about his financial and political ties with China.

The publication uncovered that Zhang is a member of the Thousand Talents Program, a recruitment initiative that “incentivizes scientists to illegally take intellectual property developed at U.S. universities to China,” according to the FBI. inewsource also found that Zhang was involved in testing a controversial new surgical treatment for infants with cataracts in China, and that the doctor failed to disclose to UCSD and the federal government that he is a cofounder and primary shareholder of a Chinese biotechnology company.

Zhang founded UCSD’s Institute for Genomic Medicine in 2009 and served as the university medical center’s chief of eye genetics. He joined the Thousand Talents Program in 2010 and cofounded his company CalCyte Therapeutics in the same year. Zhang never mentioned the company in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies